In April of this year, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market. In this post (Part I), we provide a 2021 year in review update on mRNA pioneers Moderna, BioNTech and CureVac, and in Part II, we profile Sanofi and other companies in the mRNA space and offer additional conclusions and outlook for 2022 and beyond.
Recent Posts
- CAFC Reverses Indefiniteness Ruling Since Claims Meet ‘Demanding’ Standard for Judicial Correction
- The Personal Side of Patents: The Battle for Life-Saving Drugs | IPWatchdog Unleashed
- CAFC Majority Reverses PTAB Obviousness Ruling Over Dissent, But Rule 36 Issues Persist for CPC Patent
- Liability Risks Before the UPC: How U.S. Companies Need to Prepare
- Other Barks & Bites for Friday, November 7: CJEU Action Against EU Commission Referred Over SEP Regulation; Ninth Circuit Affirms CoComelon Copyright Win; and C4IP Urges USTR to Address IP Concerns in USMCA Joint Review